Last week, we covered the controversial approval of the first Alzheimer’s drug in 20 years. Last year, the FDA advisory committee determined that there wasn’t enough support that the treatment is effective. According to a CNN Health article, one member of the committee has resigned in protest of the recent approval of Biogen’s experimental drug that costs $56k/year.
Alzheimer Drug Approval Leads FDA Advisor to Resign
A Mayo Clinic neurologist resigned in protest of the FDA’s questionable approval of aducanumab.
Jun 15, 2021
Recommended
Recommended
Recommended
